Integral Diagnostics Ltd. (AU:IDX)
ASX:IDX
Top Page
Integral Diagnostics Ltd.
(Sydney:IDX)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$2.50
â–²(10.13% Upside)
Action:ReiteratedDate:10/04/25
Integral Diagnostics Ltd. has strong revenue growth and operational efficiency, but faces significant challenges in profitability and cash flow management. The technical indicators suggest bearish momentum, and the stock appears overvalued with a high P/E ratio. These factors contribute to a cautious outlook, reflected in the overall score.
Positive Factors
Robust Revenue Growth
Sustained double-digit revenue expansion evidences durable demand for diagnostic imaging and successful network utilization. Over 2-6 months this supports capacity investment, payer coverage leverage and a larger recurring revenue base that underpins longer-term operational scaling and strategic options.
Negative Factors
Very Low Net Profit Margin
Extremely low net margins mean most revenue is absorbed by operating costs, interest or non-operating items, limiting retained earnings. Over the medium term this constrains reinvestment, dividend capacity and the firm's ability to build capital buffers, making sustained profitability improvement critical.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust Revenue Growth
Sustained double-digit revenue expansion evidences durable demand for diagnostic imaging and successful network utilization. Over 2-6 months this supports capacity investment, payer coverage leverage and a larger recurring revenue base that underpins longer-term operational scaling and strategic options.
Read all positive factors
Integral Diagnostics Ltd. (IDX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$846.38M
Dividend Yield2.65%
Average Volume (3M)911.20K
Price to Earnings (P/E)26.4
Beta (1Y)0.41
Revenue Growth33.54%
EPS GrowthN/A
CountryAU
Employees1,977
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.02
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.57
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.25Price Target Upside43.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.13
Revenue Forecast (FY)AU$801.31M
Integral Diagnostics Ltd. Business Overview & Revenue Model
Company Description
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services ...
How the Company Makes Money
IDX makes money primarily by delivering diagnostic imaging exams and associated radiology reporting, earning revenue on a per-scan/per-service basis. Key revenue streams typically include: (1) patient imaging services where payments are sourced fr...
Integral Diagnostics Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
65
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 767.82M | 627.22M | 469.70M | 440.10M | 358.74M | 348.81M |
| Gross Profit | 170.25M | 599.09M | 446.78M | 97.76M | 83.84M | 92.19M |
| EBITDA | 131.67M | 87.70M | 12.10M | 92.74M | 69.90M | 88.94M |
| Net Income | 14.03M | 4.67M | -60.70M | 25.04M | 14.60M | 31.27M |
Balance Sheet | ||||||
| Total Assets | 1.42B | 1.43B | 744.28M | 839.01M | 783.01M | 654.90M |
| Cash, Cash Equivalents and Short-Term Investments | 34.12M | 52.10M | 42.44M | 33.85M | 123.19M | 62.20M |
| Total Debt | 841.54M | 585.01M | 355.59M | 365.08M | 340.99M | 308.36M |
| Total Liabilities | 742.06M | 732.53M | 442.57M | 465.96M | 435.77M | 400.16M |
| Stockholders Equity | 678.25M | 693.00M | 301.71M | 373.05M | 347.24M | 254.74M |
Cash Flow | ||||||
| Free Cash Flow | 26.69M | 14.01M | 42.28M | 27.42M | 9.33M | 49.30M |
| Operating Cash Flow | 84.45M | 73.77M | 66.16M | 71.42M | 37.10M | 69.57M |
| Investing Cash Flow | -56.25M | -64.99M | -27.90M | -128.96M | -55.69M | -56.66M |
| Financing Cash Flow | -24.89M | 710.00K | -29.45M | -31.85M | 81.13M | -7.83M |
Integral Diagnostics Ltd. Technical Analysis
Negative
2.27
Price Trends
2.39
Negative
2.44
Negative
2.55
Negative
Market Momentum
-0.03
Positive
41.94
Neutral
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Negative. The current price of 2.27 is below the 20-day moving average (MA) of 2.34, below the 50-day MA of 2.39, and below the 200-day MA of 2.55, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.94 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDX.
Integral Diagnostics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$9.77B | 10.64 | 6.39% | 4.69% | 9.44% | -0.37% | |
67 Neutral | AU$259.11M | 10.00 | 6.06% | 6.22% | 6.65% | ― | |
59 Neutral | AU$390.60M | 23.92 | 16.35% | 4.60% | 6.73% | 37.16% | |
55 Neutral | AU$846.38M | 26.42 | 2.05% | 2.65% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$363.07M | -5.40 | -67.21% | ― | -23.02% | 33.11% | |
41 Neutral | AU$18.17M | -2.23 | -23.93% | ― | 62.81% | 16.37% |
* Healthcare Sector Average
AU:IDX
Integral Diagnostics Ltd.
2.27
0.07
3.28%
AU:HLS
Healius Limited
0.50
-0.52
-51.17%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.30
-78.67%
AU:SHL
Sonic Healthcare Limited
19.77
-3.91
-16.52%
AU:ACL
Australian Clinical Labs Ltd
2.07
-0.76
-26.75%
AU:MVF
Monash IVF Group Ltd
0.67
-0.01
-1.77%
Integral Diagnostics Ltd. Corporate Events
Integral Diagnostics Director Increases Indirect Stake via Dividend Reinvestment
Apr 2, 2026
Integral Diagnostics has disclosed a change in the indirect shareholding of director James Tobias Hall, reflecting routine participation in the company’s dividend reinvestment plan. Through his self-managed superannuation fund structure, Hal...
Integral Diagnostics Seeks ASX Quotation for New Dividend Plan Shares
Apr 2, 2026
Integral Diagnostics Ltd., an ASX-listed provider of diagnostic imaging services, has confirmed the issue of additional ordinary fully paid shares. The company operates in the healthcare sector, supplying radiology and diagnostic solutions to medi...
Integral Diagnostics Reports Lapse of Employee Performance Rights
Apr 2, 2026
Integral Diagnostics Ltd., the ASX-listed diagnostic imaging provider, has reported changes to its capital structure following the lapse of certain employee incentive securities. The company confirmed that a tranche of long-term incentive performa...
Integral Diagnostics Announces Departure of Director Raelene Murphy
Apr 1, 2026
Integral Diagnostics Ltd. has announced that non-executive director Raelene Murphy has ceased to be a director of the company effective 31 March 2026. The filing discloses that Murphy held 49,945 fully paid ordinary shares in the company at the ti...
Integral Diagnostics updates FX and DRP details for December-half dividend
Mar 25, 2026
Integral Diagnostics Ltd., the ASX-listed diagnostic imaging provider trading under ticker IDX, has confirmed updated details for its latest dividend relating to the six-month period ended 31 December 2025. The payment is tied to ordinary fully pa...
Integral Diagnostics Sets August 2026 Start Date for New CEO
Mar 24, 2026
Integral Diagnostics has confirmed that incoming Managing Director and Chief Executive Officer Jason Martinez will commence his role on 6 August 2026, following an extended garden leave period with his former employer. The timing finalises a key l...
Integral Diagnostics director James Hall increases indirect shareholding
Mar 9, 2026
Integral Diagnostics Limited has disclosed a change in the interests of director James Tobias Hall, who holds his stake indirectly via SF Nominees Pty Ltd as trustee for a self-managed super fund. The filing notes that the director is both a direc...
Integral Diagnostics Director Laura McBain Increases Indirect Shareholding
Mar 8, 2026
Integral Diagnostics has disclosed a change in the shareholding of non-executive director Laura McBain, who increased her indirect interest in the company through an on-market purchase. Via Vermilion 21 Pty Ltd as trustee for the McNelhaus Super F...
Integral Diagnostics Director Kevin Shaw Purchases Initial Shareholding
Mar 1, 2026
Integral Diagnostics has disclosed a change in director Kevin Shaw’s interests, with Shaw acquiring 28,000 fully paid ordinary shares in the company via an on-market trade. The purchase, executed on 27 February 2026 at $2.43 per share, marks...
Integral Diagnostics Director Increases Indirect Shareholding
Mar 1, 2026
Integral Diagnostics director Ingrid Anne Player has increased her indirect shareholding in the company, reflecting a higher personal financial exposure to the medical imaging provider. Her interests are held through Pisi Pty Ltd as trustee of The...
Integral Diagnostics Declares Interim Dividend for December 2025 Half-Year
Feb 23, 2026
Integral Diagnostics Ltd., an ASX-listed provider of diagnostic imaging services under ticker IDX, continues to position itself as a stable healthcare services company offering income returns to shareholders through dividends on its ordinary fully...
Integral Diagnostics Delivers Strong 1H FY26 Results as Capitol Merger Synergies Exceed Targets
Feb 23, 2026
Integral Diagnostics has reported a strong first-half FY26 performance, underpinned by the recent merger with Capitol Health, which has expanded its operational scale and clinic network. The group delivered revenue of $393.5 million, up 55.6%, and...
Integral Diagnostics Swings to Profit and Lifts Interim Dividend
Feb 23, 2026
Integral Diagnostics has reported a sharp turnaround in its half-year results to 31 December 2025, with revenue from ordinary activities jumping 55.6% to $393.5 million and EBITDA rising 91.4% to $67.1 million. EBIT climbed 161.8% to $30.2 million...
Integral Diagnostics Cancels 37,488 Long-Term Incentive Performance Rights
Jan 23, 2026
Integral Diagnostics Ltd has notified the market of the cessation of 37,488 IDXAA long-term incentive performance rights, which were cancelled by agreement between the company and the holder effective 16 January 2026. The cancellation marginally r...
Integral Diagnostics Sets Investor Call for FY26 Half-Year Results
Jan 15, 2026
Integral Diagnostics has scheduled a group investor conference call for 11:00am AEDT on 24 February 2026, to be held following the release of its FY26 half-year financial results earlier that day. The planned briefing underscores the company’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.